Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  olaparib
Find trials that include:  Any drugs shown
Results 1-16 of 16 for your search:
Start Over
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-GY005, NCI-2015-00651, NCT02502266
Olaparib in Treating Patients with Triple-Negative Non-metastatic Breast Cancer Who Have Completed Definitive Local Treatment and Chemotherapy
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment
Age: 18 and over
Trial IDs: NSABP-B-55, NCI-2014-00644, B-55/BIG 6-13, BIG 6-13, D081CC00006, NSABP B-55/BIG 6-13, NCT02032823
Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: D081FC00001, NCI-2015-00038, 2014-001589-85, NCT02184195
Olaparib or Cediranib Maleate and Olaparib Compared with Standard Platinum-Based Chemotherapy in Treating Patients with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: Not specified
Trial IDs: NRG-GY004, NCI-2015-00606, NCT02446600
Olaparib and mTOR Kinase Inhibitor AZD2014 or AKT Inhibitor AZD5363 in Treating Patients with Recurrent Endometrial, Triple Negative Breast, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0784, NCI-2014-01973, NCT02208375
Olaparib and Temozolomide in Treating Patients with Recurrent Small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 15-121, NCI-2015-01724, NCT02446704
Durvalumab and Olaparib or Cediranib Maleate in Treating Patients with Advanced Solid Tumors or Recurrent Ovarian, Breast, Lung, Prostate, or Colorectal Cancers
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-C-0145, NCI-2015-01401, P141726, NCT02484404
Olaparib and Tremelimumab in Treating BRCA1 or BRCA2 Mutation Carrier Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 99
Trial IDs: INST 1419, NCI-2016-00434, NCT02571725
Olaparib and Cediranib Maleate in Treating Patients with Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9825, NCI-2015-00051, PENDING, NCT02345265
A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9881, NCI-2015-01097, TBD, NCT02498613
Olaparib in Treating Patients with Stage IV Pancreatic Cancer
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2015-0503, NCI-2016-00351, NCT02677038
Buparlisib or Alpelisib and Olaparib in Treating Patients with Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-159, NCI-2012-01929, CBKM120ZUS32T, ISS22810064, NCT01623349
Olaparib and Cetuximab Together With Radiation Therapy in Treating Patients With Stage III or IVA-B Head and Neck Cancer With Heavy Smoking Histories
Status: Active
Phase: Phase I
Type: Treatment
Age: Over 18
Trial IDs: 11-1658, NCI-2012-02945, NCT01644266, NCT01758731
Olaparib and Temozolomide with or without Irinotecan in Treating Patients with Recurrent or Metastatic Ewing Sarcoma Previously Treated with Chemotherapy
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-115, NCI-2013-01821, NCT01858168
Cisplatin, Paclitaxel, Bevacizumab, and Olaparib in Treating Patients with Newly Diagnosed Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Undergone Initial Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-220, NCI-2014-01020, NCT02121990
Start Over